JP2021100937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021100937A5 JP2021100937A5 JP2021031431A JP2021031431A JP2021100937A5 JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5 JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- equation
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000008919 Achondroplasia Diseases 0.000 claims 2
- 206010008723 Chondrodystrophy Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 230000022159 cartilage development Effects 0.000 claims 1
Claims (9)
- 前記c1は約225である、請求項1に記載の化合物又は製薬上許容されるその塩。
- 前記c1は約225である、請求項3又は4に記載の化合物又は製薬上許容されるその塩。
- 請求項1〜5のいずれか1項に記載の少なくとも1つの化合物又は製薬上許容されるその塩、及び少なくとも1つの賦形剤を含む医薬組成物。
- 医薬として使用される、請求項1〜5のいずれか1項に記載の化合物若しくは製薬上許容されるその塩、又は請求項6に記載の医薬組成物。
- 前記医薬が、軟骨形成不全、低軟骨形成症、低身長症、ヌーナン症候群、及びSHOX欠損症からなる群から選択される疾患の治療に使用される、請求項7に記載の化合物若しくは製薬上許容されるその塩、又は医薬組成物。
- 前記疾患が軟骨形成不全である、請求項8に記載の化合物若しくは製薬上許容されるその塩、又は医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16150624 | 2016-01-08 | ||
EP16150624.1 | 2016-01-08 | ||
EP16179286.6 | 2016-07-13 | ||
EP16179286 | 2016-07-13 | ||
EP16191458.5 | 2016-09-29 | ||
EP16191458 | 2016-09-29 | ||
JP2018535304A JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するcnpプロドラッグ |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018535304A Division JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するcnpプロドラッグ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021100937A JP2021100937A (ja) | 2021-07-08 |
JP2021100937A5 true JP2021100937A5 (ja) | 2021-08-26 |
JP6951597B2 JP6951597B2 (ja) | 2021-10-20 |
Family
ID=57838356
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するcnpプロドラッグ |
JP2021031431A Active JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するcnpプロドラッグ |
JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するcnpプロドラッグ |
JP2023147381A Pending JP2023175776A (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するcnpプロドラッグ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するcnpプロドラッグ |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するcnpプロドラッグ |
JP2023147381A Pending JP2023175776A (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するcnpプロドラッグ |
Country Status (8)
Country | Link |
---|---|
US (4) | US10835578B2 (ja) |
EP (1) | EP3400020A1 (ja) |
JP (4) | JP7051686B2 (ja) |
AU (2) | AU2017205268B2 (ja) |
CA (1) | CA3007976C (ja) |
MX (1) | MX2018008061A (ja) |
WO (1) | WO2017118693A1 (ja) |
ZA (1) | ZA201804414B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3007976C (en) * | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
EP3400018A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
AU2017205693B2 (en) * | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
CN115177720A (zh) | 2016-01-08 | 2022-10-14 | 阿森迪斯药物生长障碍股份有限公司 | 具有低npr-c结合的控制释放cnp激动剂 |
KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
KR20190125310A (ko) | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
US20210024602A1 (en) * | 2018-03-28 | 2021-01-28 | Ascendis Pharma Oncology Division A/S | IL-2 Conjugates |
WO2020053815A1 (en) | 2018-09-12 | 2020-03-19 | Quiapeg Pharmaceuticals Ab | Releasable glp-1 conjugates |
MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
JP2023530273A (ja) * | 2020-06-12 | 2023-07-14 | ファーマイン コーポレイション | C型ナトリウム利尿ペプチド及び癌の処置におけるその方法 |
CA3236278A1 (en) * | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
SG159381A1 (en) | 2001-10-10 | 2010-03-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
CN100558398C (zh) | 2002-11-26 | 2009-11-11 | 拜奥康有限公司 | 修饰的钠尿化合物、缀合物及其应用 |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
SI1620118T1 (sl) | 2003-04-08 | 2014-11-28 | Yeda Research And Development Co., Ltd. | Reverzibilna pegilirana zdravila |
ES2741524T3 (es) | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
MX2009002504A (es) | 2006-09-08 | 2009-05-22 | Mayo Foundation | Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora. |
EP2063709A2 (en) | 2006-09-15 | 2009-06-03 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
CA2668814A1 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
US7798220B2 (en) * | 2007-04-20 | 2010-09-21 | Shell Oil Company | In situ heat treatment of a tar sands formation after drive process treatment |
KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | C型ナトリウム利尿ペプチドの変異体 |
CN101980725B (zh) * | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
EP2334335A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
HRP20220057T1 (hr) * | 2009-05-20 | 2022-04-15 | Biomarin Pharmaceutical Inc. | Varijante natriuretičnog peptida c-tipa |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
CN103025164B (zh) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | 从固体支撑物中药物的控制释放 |
WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
CA2843875C (en) | 2011-08-12 | 2020-01-07 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
WO2013024048A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
WO2013024053A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
JP6092867B2 (ja) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー/エス | 担体連結しているトレプロスチニルプロドラッグ |
US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
AU2013254756B2 (en) | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
CA2871579A1 (en) | 2012-04-25 | 2013-10-31 | Daiichi Sankyo Company, Limited | Use of a c-type natriuretic peptide as a bone repair promoter |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
JPWO2015129812A1 (ja) | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
AU2015299055C1 (en) | 2014-08-06 | 2021-05-06 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
WO2016110577A1 (en) | 2015-01-09 | 2016-07-14 | Ascendis Pharma A/S | Cnp prodrugs |
US11202819B2 (en) | 2015-12-08 | 2021-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
CN115177720A (zh) | 2016-01-08 | 2022-10-14 | 阿森迪斯药物生长障碍股份有限公司 | 具有低npr-c结合的控制释放cnp激动剂 |
EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
EP3400018A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
KR102531327B1 (ko) * | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
-
2017
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en active Application Filing
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP2023175776A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021100937A5 (ja) | ||
JP2004509061A5 (ja) | ||
JP2020507589A5 (ja) | ||
JP2020097577A5 (ja) | ||
JP2018048154A5 (ja) | ||
JP2007501809A5 (ja) | ||
JP2006526590A5 (ja) | ||
JP2012529486A5 (ja) | ||
RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
JP2006514012A5 (ja) | ||
JP2013507439A5 (ja) | ||
JP2005523922A5 (ja) | ||
JP2006523216A5 (ja) | ||
JP2005532332A5 (ja) | ||
JP2004504406A5 (ja) | ||
JP2004505095A5 (ja) | ||
JP2005508337A5 (ja) | ||
JP2004531549A5 (ja) | ||
JP2006528152A5 (ja) | ||
JP2020532547A5 (ja) | ||
JP2007520452A5 (ja) | ||
JP2019515908A5 (ja) | ||
JP2005526833A5 (ja) | ||
JP2002528502A5 (ja) | ||
JP2009506043A5 (ja) |